Therapies / Biology / Cancer / Life Sciences / Europe / Science / Biologic / Biological / Drug / Drugs / Boston blog main / Boulder / Denver blog main / Detroit blog main / Europe blog main / Indiana blog main / National blog main / New York blog main / Raleigh-Durham blog main / San Diego blog main / San Francisco blog main / Seattle blog main / Texas blog main / Wisconsin blog main / BIO Europe Spring / Biotech / EBD Group / Khatereh Ahmadi / Merck / MSD / Oncology / Regina Hodits / Wellington Partners

Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel

Posted On: Mar 26, 2020   |   Posted By: Xconomy

Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel

Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs. That's the message life sciences experts shared this week during a webcast on the topic of “oncology's next decade” recorded for the BIO-Europe Spring partnering conference. The event is produced by EBD Group, which is owned by the same parent company as Xconomy, and was held virtually given coronavirus concerns. “I think the conversion of the coming together of different therapies and different paradigm shifts that we have been through, be it targeted therapy, biologics, or going back earlier,...

Continue reading ...